| Assay ID | Title | Year | Journal | Article |
|---|
| AID1185901 | Inhibition of Axl (unknown origin) by Off-chip Mobility Shift Assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185883 | Half life in Swiss albino mouse at 3 mg/kg, iv | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1409258 | Inhibition of N-terminal GST-tagged human TYRO3 cytoplasmic domain (453 to 890 end residues) expressed in baculovirus expression system using fluorecence-labeled substrate by MCE assay | 2018 | Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
| Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group. |
| AID1409255 | Inhibition of N-terminal GST-tagged human TRKA cytoplasmic domain (436 to 790 end residues) expressed in baculovirus expression system using fluorecence-labeled substrate by MCE assay | 2018 | Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
| Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group. |
| AID1185887 | Clearance in Swiss albino mouse at 3 mg/kg, iv | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1409257 | Inhibition of N-terminal GST-tagged full length human QIK (1 to 926 end residues) expressed in baculovirus expression system using fluorecence-labeled substrate by MCE assay | 2018 | Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
| Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group. |
| AID1409256 | Inhibition of N-terminal GST-tagged human TRKC cytoplasmic domain (456 to 825 end residues) expressed in baculovirus expression system using fluorecence-labeled substrate by MCE assay | 2018 | Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
| Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group. |
| AID1409261 | Inhibition of N-terminal GST-tagged human KIT cytoplasmic domain (544 to 976 end residues) expressed in baculovirus expression system using fluorecence-labeled substrate by MCE assay | 2018 | Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
| Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group. |
| AID1185922 | Selectivity ratio of IC50 for EGFR extracellular/transmembrane domain-tagged Axl intracellular domain (unknown origin) expressed in 32D cells assessed as inhibition EGF-stimulated of phosphorylation to IC50 for EGFR extracellular/transmembrane domain-tagg | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185911 | Inhibition of Mer phosphorylation in human 697 cells by ATP ActivX probe assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185914 | Inhibition of Flt3 phosphorylation in human Molm-14 cells preincubated for 1 hr by densitometry | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185884 | Cmax in Swiss albino mouse at 3 mg/kg, iv | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185909 | Inhibition of Met (unknown origin) by Off-chip Mobility Shift Assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185921 | Inhibition of EGFR extracellular/transmembrane domain-tagged Tyro3 intracellular domain (unknown origin) expressed in 32D cells assessed as inhibition EGF-stimulated of phosphorylation pretreated for 1 hr prior to EGF stimulation by Western blot analysis | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185910 | Selectivity ratio of IC50 for Met (unknown origin) to IC50 for Mer (unknown origin) | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185913 | Inhibition of Mer phosphorylation in human 697 cells preincubated for 1 hr by densitometry | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185920 | Inhibition of EGFR extracellular/transmembrane domain-tagged Axl intracellular domain (unknown origin) expressed in 32D cells assessed as inhibition EGF-stimulated of phosphorylation pretreated for 1 hr prior to EGF stimulation by Western blot analysis | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185906 | Inhibition of SLK (unknown origin) by Off-chip Mobility Shift Assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185927 | Fraction unbound in plasma of human 697 cells xenografted NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mouse at 3 mg/kg, po administered as single dose measured after 30 mins post dose | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1409253 | Inhibition of N-terminal GST-tagged human MERTK cytoplasmic domain (528 to 999 end residues) expressed in baculovirus expression system using fluorecence-labeled substrate by MCE assay | 2018 | Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
| Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group. |
| AID1185886 | Volume of distribution at steady state in Swiss albino mouse at 3 mg/kg, iv | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185926 | Plasma protein binding in human 697 cells xenografted NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mouse at 3 mg/kg, po administered as single dose measured after 30 mins post dose | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185917 | Inhibition of Flt3-mediated colony formation in human Molm-14 cells at 10 to 50 nM measured after 2 weeks by soft agar colony formation assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185888 | Tmax in Swiss albino mouse at 3 mg/kg, po | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185908 | Inhibition of Kit (unknown origin) by Off-chip Mobility Shift Assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1409252 | Inhibition of N-terminal GST-tagged human FLT3 cytoplasmic domain (564 to 993 end residues) expressed in baculovirus expression system using fluorecence-labeled substrate by MCE assay | 2018 | Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
| Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group. |
| AID1409259 | Inhibition of N-terminal GST-tagged full length human SLK (1 to 1152 end residues) expressed in baculovirus expression system using fluorecence-labeled substrate by MCE assay | 2018 | Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
| Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group. |
| AID1185915 | Inhibition of Mer-mediated colony formation in human A549 cells at 50 to 300 nM measured after 2 weeks by soft agar colony formation assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1409260 | Inhibition of N-terminal GST-tagged full length human NuaK1 (1 to 661 end residues) expressed in baculovirus expression system using fluorecence-labeled substrate by MCE assay | 2018 | Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
| Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group. |
| AID1185923 | Selectivity ratio of IC50 for EGFR extracellular/transmembrane domain-tagged Tyro3 intracellular domain (unknown origin) expressed in 32D cells assessed as inhibition EGF-stimulated of phosphorylation to IC50 for EGFR extracellular/transmembrane domain-ta | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185891 | Oral bioavailability in Swiss albino mouse at 3 mg/kg | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185924 | Inhibition of Mer phosphorylation in human 697 cells xenografted in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mouse at 3 mg/kg, po administered as single dose measured after 30 mins post dose by densitometry relative to control | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185907 | Inhibition of Nuak1 (unknown origin) by Off-chip Mobility Shift Assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1409263 | Ratio of IC50 for MERTK (unknown origin) using 5'-FAM-EFPIYDFLPAKKK-CONH2 as substrate after 180 mins by MCE assay to IC50 for N-terminal GST-tagged human MERTK cytoplasmic domain (528 to 999 end residues) expressed in baculovirus expression system using | 2018 | Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
| Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group. |
| AID1185902 | Inhibition of Tyro3 (unknown origin) by Off-chip Mobility Shift Assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185889 | Cmax in Swiss albino mouse at 3 mg/kg, po | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185881 | Inhibition of Mer (unknown origin) by Off-chip Mobility Shift Assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185904 | Inhibition of TRKC (unknown origin) by Off-chip Mobility Shift Assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185905 | Inhibition of QIK (unknown origin) by Off-chip Mobility Shift Assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1409254 | Inhibition of N-terminal GST-tagged human AXL cytoplasmic domain (464 to 885 end residues) expressed in baculovirus expression system using fluorecence-labeled substrate by MCE assay | 2018 | Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
| Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group. |
| AID1185925 | Plasma concentration in human 697 cells xenografted NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mouse at 3 mg/kg, po administered as single dose measured after 30 mins post dose | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185903 | Inhibition of TRKA (unknown origin) by Off-chip Mobility Shift Assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1409262 | Inhibition of N-terminal GST-tagged human MERTK cytoplasmic domain (528 to 999 end residues) expressed in baculovirus expression system at 100 nM using fluorecence-labeled substrate by MCE assay relative to control | 2018 | Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
| Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group. |
| AID1185885 | AUClast in Swiss albino mouse at 3 mg/kg, iv | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185919 | Inhibition of EGFR extracellular/transmembrane domain-tagged Mer intracellular domain (unknown origin) expressed in 32D cells assessed as inhibition EGF-stimulated of phosphorylation pretreated for 1 hr prior to EGF stimulation by Western blot analysis | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185890 | AUClast in Swiss albino mouse at 3 mg/kg, po | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1185882 | Inhibition of Flt3 (unknown origin) by Off-chip Mobility Shift Assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347412 | qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |